Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-7x19 CAR-T and Tislelizumab in R/R DLBCL
NCT04381741Phase 1Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jun 2020
- Primary completion
- Sep 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NIB-101 in diffuse large B-cell lymphoma (DLBCL), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Objective Response Rate at 3 months. Status: unknown.
02
Drugs
NIB-101
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04381741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04381741.